BEYOND AIR INC. - COMMON STOCK

Beyond Air® to Report First Fiscal Quarter 2025 Financial Results on August 6

23 Jul 2024 16:05:00 By Nasdaq GlobeNewswire

Beyond Air® To Participate in the BTIG Virtual Biotechnology Conference 2024

16 Jul 2024 16:05:00 By Nasdaq GlobeNewswire

Beyond Air® Reports Fiscal Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

24 Jun 2024 16:15:00 By Nasdaq GlobeNewswire

Beyond Air® Appoints David Webster as Chief Commercial Officer

13 Jun 2024 16:05:00 By Nasdaq GlobeNewswire

Beyond Cancer Presents First-in-Class Clinical Data Showing an Immunogenic Response in Subjects with r/r Unresectable Solid Tumors Treated with Ultra-High Concentration Nitric Oxide (UNO)

03 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Beyond Air® Schedules Fiscal Year End 2024 Financial Results Conference Call and Webcast

23 May 2024 16:09:12 By Nasdaq GlobeNewswire

Beyond Cancer Selected to Present on the Clinical Development of Ultra-High Concentration Nitric Oxide (UNO) Therapy at the 2024 American Society of Clinical Oncology Annual Meeting

01 May 2024 07:00:00 By Nasdaq GlobeNewswire

Beyond Air® Announces Pricing of $16.0 Million Registered Direct Offering of Common Stock and Warrants

20 Mar 2024 09:00:00 By Nasdaq GlobeNewswire

Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2024

12 Feb 2024 16:05:00 By Nasdaq GlobeNewswire

Beyond Air® Schedules Third Fiscal Quarter 2024 Financial Results Conference Call and Webcast

18 Jan 2024 08:00:00 By Nasdaq GlobeNewswire

Beyond Cancer™ Phase 1 Study Clears Cohort 1 in Patients with Advanced Relapsed or Refractory Unresectable Primary or Metastatic Cutaneous or Subcutaneous Solid Tumors

27 Dec 2023 07:30:00 By Nasdaq GlobeNewswire

Beyond Air® To Participate in the 35th Annual Piper Sandler Healthcare Conference

15 Nov 2023 16:05:00 By Nasdaq GlobeNewswire

Beyond Air® Reports Financial Results for Second Quarter of Fiscal Year 2024

13 Nov 2023 16:05:00 By Nasdaq GlobeNewswire

Beyond Cancer™ Presents Positive First-in-Human Clinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

03 Nov 2023 12:00:00 By Nasdaq GlobeNewswire

Beyond Air® Schedules Second Fiscal Quarter 2024 Financial Results Conference Call and Webcast

19 Oct 2023 16:05:00 By Nasdaq GlobeNewswire

Beyond Air® To Participate in the Truist Securities BioPharma Symposium

17 Oct 2023 16:05:00 By Nasdaq GlobeNewswire

Beyond Cancer™ Publishes Pre-Clinical Data in Cells Demonstrating that the Combination of Ultra-High Concentration Nitric Oxide (UNO) and Anti-mPD-1 Therapy Improves Tumor Regression Rates and Survival in Mice

17 Oct 2023 07:30:00 By Nasdaq GlobeNewswire

Beyond Cancer™ Presents Positive Preclinical Data for Ultra-High Concentration Nitric Oxide (UNO) in Combination with Checkpoint Inhibitor Therapy During the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

16 Oct 2023 07:30:00 By Nasdaq GlobeNewswire

Beyond Air® Receives Innovative Technology Contract from Vizient for LungFit®PH

16 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Beyond Cancer™ Selected to Present Proffered Posters Discussing Data from the UNO Therapy Program at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

04 Oct 2023 07:30:00 By Nasdaq GlobeNewswire